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Dopamine dysregulation syndrome (DDS) consists of a series of complications such as compulsive use of
dopaminergic medications, aggressive or hypomanic behaviors during excessive use, and withdrawal states
characterized by dysphoria and anxiety, caused by long-term dopaminergic treatment in patients with Parkinson’s
disease (PD). Although several ways to manage DDS have been suggested, there has been no established treatment
that can manage DDS without deterioration of motor symptoms. In this article, we present a case of PD in whom
the administration of the dopamine D2 partial agonistic antipsychotic drug aripiprazole improved DDS symptoms
such as craving and compulsive behavior without worsening of motor symptoms. Considering the profile of this
drug as a partial agonist at D2 receptors, it is possible that it exerts its therapeutic effect on DDS by modulating the
dysfunctional dopamine system.
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In the course of long-term antiparkinson therapy,
patients with Parkinson’s disease (PD) often develop dis-
inhibitory non-motor pathologies such as dopamine dys-
regulation syndrome (DDS) and impulse control
disorders (ICD) including pathological gambling, hyper-
sexuality and compulsive buying. Occasionally, punding
or preoccupied repetitive behavior is also observed with
DDS or ICD. DDS refers to excessive and compulsive
use of dopaminergic medications well beyond the dose
needed to control motor symptoms, and it has been typ-
ically recognized as a consequence of dopamine replace-
ment therapy (DRT). Patients with DDS show aggressive
or hypomanic behaviors during episodes of excessive use,
as well as withdrawal states characterized by dysphoria
and anxiety. DDS may improve with reduction of the
dosage of the dopaminergic agent, but many patients are
reluctant to decrease levodopa, showing an enduring
tendency to relapse [1]. Here, we report the successful* Correspondence: motokato@tc4.so-net.ne.jp
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reproduction in any medium, provided the ortreatment of DDS in a PD patient with a dopamine D2
partial agonistic antipsychotic drug.Case presentation
The patient is a 63-year-old male who was diagnosed with
PD at age 48, when he began suffering from shuffling gait
of the right foot. He had no previous history of alcohol or
drug abuse. He also had no history of smoking. Initially, he
had been treated with amantadine and pramipexole. How-
ever, within six years, symptoms had worsened and rigidity
of the whole body set in. Medication was then switched to
levodopa/benserazide. Hoehn & Yahr Scale at this time
was ranked as stage II. In the following years, he repeatedly
complained of lower back pain and anxiety. Several medi-
cations including noritriptyline could not alleviate his pain,
and only levodopa was beneficial. Nine years after begin-
ning DRT, the patient started self-medication, using exces-
sive doses of levodopa— up to 2000 mg a day. At the time
he was referred to our hospital, he demonstrated compul-
sive use of levodopa and a withdrawal state including de-
pressive symptoms such as anhedonia, loss of interest and
back pain, with impaired social functioning. These depres-
sive symptoms were not accompanied with psychoticral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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preoccupation with repetitive tasks such as carpentry and
gardening; he often started to strike nails with a hammer
suddenly, continuing all day and into the night. EEG and
brain MRI demonstrated no abnormal findings, and verbal
and performance IQ on WAIS-R were 110 and 98, re-
spectively. Based on the development of compulsive use
through levodopa therapy, he was diagnosed with DDS.
At first, reduction of levodopa medication was initiated
and the patient tried his best not to take excessive medi-
cations. However, he could not cease the excessive use of
levodopa. At this point, treatment with aripiprazole at
6 mg/day was begun. By eleven months, with the dosage
of aripiprazole having been raised to 18 mg/day, his crav-
ing for medications (daily dosages and intake intervals)
had considerably subsided. After one year of aripiprazole
therapy, the dose of levodopa was reduced to 600 mg/
day without compulsive use, and no punding behavior
was observed. His lower back pain also showed marked
improvement, and his depressive symptoms diminished
without worsening of motor symptoms. Adverse reac-
tions related to aripiprazole including insomnia, akathi-
sia, restlessness and sedation were not observed.
Discussion
Within the past decade, DDS has become recognized as
an important complication of dopamine replacement
therapy, and several medical and surgical options for
DDS have been suggested. One such option is subthala-
mic nucleus deep brain stimulation (DBS), which is
accepted as an effective treatment of DDS [2]. However,
DBS is not without risks, including side effects following
surgery, impaired cognitive function and psychiatric
complications [3]. Interventions including psychotherapy
and social support are sometimes useful, but these have
only a limited effect in the treatment of DDS. At present,
the first line of treatment for DDS is generally medica-
tion rationalization. It has been reported that reduction
in dopaminergic drug therapies could improve the dis-
ability caused by the behavioral disorders associated with
DDS. However, dosage reduction of the dopaminergic
agent can be troublesome due to worsening of motor
symptoms and neuropsychiatric withdrawal symptoms.
Furthermore, in the situation where patients may remain
sensitized to the dopaminergic agent’s rewarding effects,
it is often difficult to reduce its dosage. Therefore, a
more effective and safe way to manage the addictive li-
ability of the dopaminergic agent is needed. In this re-
port, we described the therapeutic effect of a dopamine
D2 partial agonistic antipsychotic drug on DDS in a pa-
tient with PD.
Several risk factors of DDS have been identified. The use
of dopaminergic agents (especially chronic exposure to
high doses of DRT), a previous history of mood disordersand alcohol dependence have shown to be relevant to the
development of DDS in PD [4]. In our case, the patient
had none of these risk factors except for high doses of
levodopa, reportedly the most important risk factor for
DDS. Although the exact mechanism underlying DDS
remains unknown, it has been postulated that the addictive
liability of dopaminergic agents is mediated by dysregula-
tion of ventral striatal dopamine neurotransmission and
abnormal activities of related neural circuitries that consti-
tute the reward systems [5]. Supporting this hypothesis,
human PET studies using [11C]-raclopride showed
enhanced drug-induced dopamine neurotransmission in
the ventral striatum in PD patients with DDS compared to
those without DDS [5]. Thus, alleviation of hyperdopami-
nergic neurotransmission in the ventral striatum is a po-
tential target in the treatment of DDS.
In the present case, we used aripiprazole for the treat-
ment of DDS. There were three reasons for this clinical
choice. First, aripiprazole has a unique pharmacological
profile that includes partial agonism at dopamine D2
receptors; it functions as an antagonist in conditions of
high, but as an agonist in conditions of low activity of
the dopamine D2 system [6].This means that aripiprazole
may exert its therapeutic effect via modulation of the
dopamine system by acting as antagonist during high
dopaminergic tone and as agonist during the withdrawal
state, and thus the dopamine D2 partial agonistic anti-
psychotic drug might represent an effective treatment
choice for the compulsive use of levodopa.
The second reason for choosing aripiprazole is its very
low risk of adverse effects on motor symptoms of PD [7].
It has been reported that even at full receptor occupancy
by aripirazole, extrapyramidal side effects comparable to
those expected with other antipsychotics such as haloperi-
dol do not occur due to its intrinsic activity on dopamine
D2 receptors [8]. Also, recent human PET studies of aripi-
prazole using [11C]raclopride and [11C]FLB457 indicate
that its intrinsic dopaminergic signal due to its partial
agonism at dopamine D2 receptors, rather than regional
distribution of dopamine D2 receptor occupancy, contrib-
ute to the minimal risk of extrapyramidal side effects [9].
Thus, D2 partial agonistic antipsychotic drug displays its
therapeutic effects with a minimum possibility of extrapyr-
amidal side effects. On the other hand, aripiprazole should
be used with caution for the treatment of psychosis in PD,
because aripiprazole generally has the adverse effects of
worsened motor signs and symptoms [10]. However, one
previous study suggested that the low doses of aripiprazole
might be tolerable in treatment of PD and display a signifi-
cant decrease in the intensity and frequency of L-dopa-
induced dyskinesias [11].
Thirdly, several studies have demonstrated the efficacy of
the dopamine D2 partial agonistic antipsychotic drug
against the compulsive use of alcohol and psychostimulants
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levodopa-seeking behavior and hoarding associated with
disabling mood, which share common characteristics of
substance dependence. Given the putative action mechan-
isms of aripiprazole described above, as well as its target
areas including the frontal-subcortical circuit that subserves
reward/craving and compulsive behavior, it is hypothesized
that the modulating effect of aripiprazole on the dysfunc-
tional dopamine system contributed to the improvement of
DDS symptoms. Thus, it may be considered that the use of
a dopamine D2 partial agonistic antipsychotic drug presents
a potentially therapeutic approach for DDS.
Several limitations to these preliminary results should
be noted. First, our finding must be interpreted with
some caution because it was based on a single case
study. Second, the optimal dose setting of aripiprazole
for the treatment of DDS has not been determined.
Thus, clinical studies with a more systematic design and
a greater number of patients are needed to elucidate the
efficacy of aripiprazole for DDS.
Conclusions
In our case, aripiprazole successfully improved DDS
without worsening motor symptoms. To our knowledge,
this is the first case report to present the efficacy of a
dopamine D2 partial agonistic antipsychotic drug for DDS
symptoms, and further clinical studies are encouraged.
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